Fluconazole is the most commonly used antifungal agent for both the treatment of cryptococcal meningitis, and for prophylaxis against the disease. However, its prolonged use has the potential to exert selection pressure in favour of fluconazoleresistant strains. We evaluated the prevalence of fluconazole resistance in Cryptococcus spp. clinical isolates in 29 studies from 1988 to May 2017 included in EMBASE and MEDLINE databases. A total of 4995 Cryptococcus isolates from 3210 patients constituted this study; 248 (5.0%) of the isolates from relapsed episodes of cryptococcosis were included in this analysis. Eleven (38%) of the studies used minimum inhibitory concentrations (MICs) breakpoints of ≥64 μg/mL to define fluconazole resistance, 6 (21%) used ≥32 μg/mL, 11 (38%) used ≥16 μg/mL and 1 (3%) used ≤20 μg/mL. Overall, mean prevalence of fluconazole resistance was 12.1% (95% confidence interval [CI]:
| INTRODUCTION
Cryptococcal meningitis (CM) is the leading cause of meningitis among persons living with HIV infection. 1 The introduction of highly active antiretroviral therapy (HAART) has led to a substantial reduction in the global incidence of cryptococcosis. However, CM still accounts for about 15% of AIDS-related mortality. reveals an estimated 223 100 annual cases; it being a major problem in developing countries; in fact, 73% of these cases (162 500) are annually diagnosed in sub-Saharan Africa. 2 Furthermore, about 70%
(range 56%-84%) of people positive for cryptococcal antigenaemia would progress to develop cryptococcal disease or die without diagnosis, unless initiated on HAART or pre-emptive fluconazole. 2 Fluconazole is a potent inhibitor of the fungal cytochrome P450-dependent lanosterol C14α-demethylase, leading to inhibition of ergosterol biosynthesis. At doses higher than 800 mg/d it shows a dose-dependent fungicidal activity against Cryptococcus spp.
4,5
Amphotericin B in combination with flucytosine for induction followed by fluconazole for consolidation and suppression therapy is the recommended antifungal regimen for the management of acute CM. 6, 7 However, in resource-limited settings where flucytosine is not routinely available, monotherapy with high dose fluconazole or in combination with amphotericin B for induction therapy is the treatment of choice. 8 Long-term maintenance therapy with fluconazole is recommended to prevent relapses following an episode of CM and in advanced HIV patients with asymptomatic cryptococcal antigenaemia. 9 For patients in whom fluconazole therapy is contraindicated, itraconazole is an acceptable but less effective alternative. 6 There is however growing concern regarding high rates of fungal persistence and recurrent CM. 6 Although antifungal drug resistance in
Cryptococcus species is relatively uncommon, the risk of development of secondary resistance among patients with relapses is a major problem. 10, 11 Fluconazole-resistant Cryptococcus was first documented in 1993 in a 30 year old HIV-infected Zambian woman diagnosed with
Cryptococcus gattii meningitis who had poor clinical and mycological response to fluconazole. 12 A few other studies in the 1990s confirmed the occurrence of fluconazole-resistant Cryptococcus infection especially in patients infected with HIV and this was linked to long-term suppressive fluconazole therapy and in patients with recurrent/relapsed cryptococcal meningitis. 13 A more recent study described a 30% (6 of 20 cases)
incidence of fluconazole-resistant Cryptococcus isolates in patients who had never had prior exposure to fluconazole, 11 this is alarming.
This systematic review aims to describe the prevalence and pattern of fluconazole-resistance in clinical isolates of Cryptococcus spp.
| METHODS
The guidance outlined in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement 14 were observed and the PRISMA check-list was used to guide this.
| Data sources and search strategies
With the help of a qualified medical librarian, we performed a systematic primary article search using EMBASE and MEDLINE databases to 
| Inclusion criteria
Randomised clinical trials, experimental studies on clinical isolates, case series and observational studies were all included.
| Exclusion criteria
Single case reports, systematic reviews and animal studies were excluded.
| Data extraction
The first and second authors independently reviewed all available titles and abstracts, and articles were selected if they fulfiled the inclusion criteria above. In cases of doubt, the third author was consulted.
Reference sections of the identified studies were also examined in order to identify additional relevant studies that were not identified by the primary literature search (Figure 1 ).
Data from selected publications extracted were: (i) study type, (ii) whether the patient case was incident, relapse or both, (iii) country the study was conducted in, (iv) the antifungal susceptibility method performed, (v) the Cryptococcus species isolated (vi) the minimum inhibitory concentration (MIC) cut-off value used to defined resistance, and (vii) the reported prevalence of resistance.
| RESULTS
Twenty-nine studies met the inclusion criteria, 21 (72.4%) were published between 2010 and 2017. Of the 4995 isolates tested in these studies, only 248 (5.0%) were from relapse episodes of CM.
Ten (34.5%) of the studies were conducted in sub-Saharan Africa, 8 (27.6%) in Europe, 5 (17.2%) in South America, 4 (13.8%) in Asia, and 2 (6.9%) in the United States of America. Half of the studies in subSaharan Africa were conducted in South Africa. With respect to the design of these published studies, majority (69.0%, n = 20) were prospective cohort or prospective population-based surveillance and the remainder 9 (31.0%) were retrospective. Table 1 shows a summary of the studies evaluated for discussion.
The clinical isolates in all these studies were obtained from HIVinfected patients diagnosed with cryptococcal disease. Cryptococcus neoformans was the most common species isolated in all the studies.
While 26 (89.7%) of the studies were conducted on isolates from incident episodes of cryptococcosis, 3 (10.3%) were from relapse/recurrent isolates, and 2 (7.0%) was from a mixture of both. Most of the studies, (n = 22, 75.9%), used broth microdilution MIC determination technique with either the Clinical Laboratory Standards Institute (CLSI) or The European Committee on Antimicrobial Susceptibility Testing (EUCAST) alone or in combination with E-test (n = 3, 13.6%) for fluconazole susceptibility testing. Eleven (38%) of the studies used MIC breakpoints of ≥64 μg/mL to define fluconazole resistance, 6 (21%) used ≥32 μg/mL, 11 (38%) used ≥16 μg/mL, and 1 (3%) used ≤20 μg/mL. T A B L E 1 (Continued)
Fluconazole resistance ranged from 0% to 50%. In seven (24.1%) studies, all isolates were fully susceptible to fluconazole. The highest resistance rates were reported in South Africa (43.6% and 50%) 16 
| DISCUSSION
In the fluconazole E-test gradient strip, the resistance was 0% amongst 300 isolates 34 ; the next year it increased to 0.6% in 487 isolates, 31 then 11% (2014) (Table 1) .
However, this might be due to the low MIC (≤16 μg/mL) cut-off used compared to other studies in this review where resistances were 10%
or less when a break point of ≤32 μg/mL is used. 29 Arechavala et al 36 from Argentina showed a 9% emergence of fluconazole resistance in relapse isolates that were fully susceptible to fluconazole at the time of diagnosis of the index episode of CM. Recurrent cryptococcal diseases is currently thought to be associated with antifungal resistance, poor compliance, changes in immune function or a combination of these circumstances. 42, 44 An earlier study has shown that fluconazole suppression therapy reduced the in vitro resistance of C. neoformans to fluconazole which was appeared to be linked to extended maintenance treatments, isolates of incident episodes of cryptococcal meningitis cases from HIVinfected patients from Cambodia showed a steep rise in fluconazole resistance from 2.5% in the first year to 14% in the second year of active laboratory based surveillance. 10 Antifungal susceptibility tests have become essential tools to guide the treatment of fungal diseases, to know the local and global disease epidemiology, and to identify resistance to antifungals. 45 The EUCAST and CLSI are responsible for the establishment and validation of MIC interpretive breakpoints for antimicrobial susceptibility testing. Antifungal susceptibility testing and molecular strain typing if possible should always be performed on relapse isolates to investigate whether the increase in resistance is due to selection pressure or whether it is a new strain. 42 Unlike polyenes and echinocandins, the mechanism of azole (eg, fluconazole) resistance is fairly well-understood. One or more of the four mechanisms contributes to azole resistance: (i) development of active efflux pump resulting into decreased drug concentration at the site of action, (ii) alteration of drug target site (the enzyme lanosterol C14α-demethylase), (iii) up-regulation of the target enzyme, and (iv) utilisation of latter sterols of the ergosterol pathways negating the action of azoles. 49 Genetic mutations in ERG11, CDR and MDR genes in Candida spp. and Cyp51A and Cyp51B genes in Aspergillus spp. have been well-described as the molecular mechanisms to azole resistance. 50 In Cryptococcus spp., fluconazole resistance phenotype has been associated with point mutation in the ERG11 gene responsible for the amino acid substitution G470R, G484S, and expression of genes that encodes for efflux mechanisms. 
